MedTrace Logo

7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication

NCT06576882 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 326

Last updated 2025-02-11

No results posted yet for this study

Summary

The study aims to test the efficacy of 7 days vs. 14 days of Vonoprazan-triple therapy in the eradication of Helicobacter Pylori infection in adolescents and young children.

Conditions

  • Helicobacter Pylori Infection
  • Gastritis
  • Vonoprazan
  • Adolescents

Interventions

DRUG

Vonoprazan

Participants will receive Vonoprazan 20 mg tablets twice daily before meals.

DRUG

Amoxicillin

Participants will receive Amoxicillin 50 mg/kg/day capsules or suspension \[maximum daily dose: 2 g\].

DRUG

Clarithromycin

Participants will receive Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose: 1 g\].

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Sameh A Lashen, MD · Alexandria University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2024-11-01
Completion
2024-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06576882 on ClinicalTrials.gov